Mast Therapeutics, Inc. (MSTX)

[lux1]

The reverse split is a cure for this stock. Culley diluted it for years until it reached a shameful amount of outstanding shares. Moreover the merger needs another redistribution among the shareholders then the R/S is inevitable as well as it is required by the NYSEMKT rules for the merger, but, for these same reasons,it shouldn't be unfavourable to Mast long.
A smaller float coupled with the lock-up period for old Savara investors and a renovated management can be finally the rebirth of the company.
IMO a market capitalization around $500M after the merger and after some positive news about trials isn't unrealistic